[199] INTEL PHARMA ANALYTICS PLATFORM TO DIGITIZE CLINICAL TRIALS

Chen Admati[1], [1] Intel Corporation

- **Investment Rational**
  The Intel® Pharma Analytics Platform is an edge-to-cloud artificial intelligence offering that helps pharmaceutical companies digitize clinical trials and improve their outcomes. The platform enables data capturing from sensors and wearable devices, and applies machine leaning to objectively measure the impact of therapies. The platform used in over a dozen of trials, collecting > 1.2 million hours from +1,000 patients.

- **Business Strategy**
  The Intel® Pharma Analytics Platform provides a technology to speed clinical trials, reduce trials costs, and gather more objective evidences. In addition, by enabling the deployment of patient-centric solutions during the clinical trial, patient burden, compliance & retention can be significantly improved. These are critical potential value dials for pharmaceutical companies to achieve better trial outcomes.

- **Core Technology**
  The Intel® Pharma Analytics Platform includes several components: (1) Sensors - the platform is sensor agnostic and enables integration of any sensor, wearable or device (2) Smartphone application - enables communication with the patient, and collections of addition info like medication regime, electronic questionnaires. (3) Backend secure cloud - store the data and apply machine learning algorithms to generate insights.

- **Product Profile/Pipeline**
  The platform is deployed in various clinical trials, with top pharmaceutical companies. We are partnering with CRO to scale to additional sponsors. We recently announced our collaboration with ICON plc. We continuously evolving our offering and look for companies, who brings to market unique sensors/devices and/or validated algorithms and would like to partner with Intel.

- **What's Next?**
  We strongly believe that computer vision and video analytics can offer advanced capabilities to improve remote monitoring of patients at home during clinical trials. We are investing in R&D work to demonstrate the value of these new concepts without compromise on patient privacy. We also look beyond drug development clinical trials to expand for post market and real-world evidence scenarios.